PTEN and glioblastoma: Afatinib-mediated EGFR inhibition was effective against all BTSCs tested; however, the degree of sensitivity was influenced by the status of common GBM molecular alterations, including EGFR mutations and PTEN inactivation (Figure 1A and Supplementary Table S1).